A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease

NCT00250393 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson's Disease

Interventions

DRUG: Istradefylline (KW-6002)

Sponsor

Kyowa Kirin Co., Ltd.